Nisa Investment Advisors
LYEL icon

Nisa Investment Advisors’s Lyell Immunopharma LYEL Stock Holding History

Nisa Investment Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351 Hold
25
– – ﹤0.01% 2989
2026
Q1 		$502 Hold
25
– – ﹤0.01% 2864
2025
Q4 		$770 Hold
25
– – ﹤0.01% 2754
2025
Q3 		$406 Hold
25
– – ﹤0.01% 2878
2025
Q2 		$221 Hold
25
– – ﹤0.01% 2993
2025
Q1 		$269 Sell
25
-9
-26% -$110 ﹤0.01% 2888
2024
Q4 		$438 Buy
34
+28
+467% +$555 ﹤0.01% 2856
2024
Q3 		$164 Sell
6
-16
-73% -$470 ﹤0.01% 2875
2024
Q2 		$638 Buy
22
+8
+57% +$381 ﹤0.01% 2632
2024
Q1 		$622 Buy
14
+6
+75% +$257 ﹤0.01% 2465
2023
Q4 		$297 Buy
+8
New +$288 ﹤0.01% 2497
2023
Q3 		– Sell
-266
Closed -$16.9K – 2809
2023
Q2 		$16.9K Buy
+266
New +$14.7K ﹤0.01% 2145
2023
Q1 		– Sell
-7
Closed – – 2617
2022
Q4 		$0 Sell
7
-295
-98% -$29.3K ﹤0.01% 2651
2022
Q3 		$36K Buy
302
+7
+2% +$948 ﹤0.01% 1867
2022
Q2 		$38K Buy
+295
New +$30.1K ﹤0.01% 1825

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Nisa Investment Advisors's LYEL Position: Q2 2026 in Review

Nisa Investment Advisors held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 25 shares worth $351. The position accounts for ﹤0.01% of the portfolio, ranked #2989.

Nisa Investment Advisors first reported a position in LYEL in Q2 2022 and has held it in 15 quarters since. The position peaked at $38K in Q2 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Nisa Investment Advisors held 25 shares of Lyell Immunopharma worth $351 as of Q2 2026.
  • Nisa Investment Advisors left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2989 holding.
  • Nisa Investment Advisors first reported a position in Lyell Immunopharma in Q2 2022 and has held it in 15 quarters since.
  • Nisa Investment Advisors's Lyell Immunopharma position peaked at $38K in Q2 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.